IP Library › Granted Patent US 7,582,726
Granted Patent B2
US 7,582,726 · App. 10/985,013 · Granted Sep 1, 2009

VEGF receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,726
App. No.
10/985,013
Granted
Sep 1, 2009
Kind
B2
Abstract

The present invention describes an approach to cancer therapy utilizing novel VEGF receptor antagonists. Specifically, the invention provides peptides and polynucleotides encoding VEGF receptor antagonists and methods of use thereof.

Claims (5)

1. A VEGF receptor antagonist consisting of KDR (Ig5-7).

2. A soluble VEGF receptor antagonist that consists essentially of SEQ ID NO:2.

3. A soluble VEGF receptor antagonist that consists essentially of SEQ ID NO:4.

4. The soluble VEGF receptor antagonist of claim 2 , consisting of SEQ ID NO:2.

5. The soluble VEGF receptor antagonist of claim 3 , consisting of SEQ ID NO:4.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2014
From: WAGNER, THOMAS E.
To: ORBIS HEALTH SOLUTIONS LLC
Reel/Frame 032665/0086 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2009
From: GHC RESEARCH DEVELOPMENT CORPORATION AND GREENVILLE HOSPITAL SYSTEM
To: WAGNER, THOMAS E.
Reel/Frame 023720/0296 →